Heat Biologics, Inc. logo
Heat Biologics, Inc. HTBX

Heat Biologics, Inc. Income Statement 2011-2026 | HTBX

Annual Income Statement Heat Biologics, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

32.8 M 8.32 M 24.8 M 10.9 M 17.8 M 19.9 M 37.1 M 28.5 M - -

Shares

4.75 M 4.75 M 2.5 M 549 K 255 K 116 K 93.4 K 54.2 K - -

Net Income

-26 M -20 M -15.7 M -11.8 M -12.6 M -20.3 M -11.8 M -8.71 M -2.42 M -2.1 M

Revenue

2.95 M 3.05 M 5.79 M 1.52 M 342 K - - - 3.11 K 188 K

EBITDA

-24.7 M -19.2 M -17.2 M -13 M -13 M -20.9 M -12.1 M -6.56 M -2.34 M -2.03 M

Operating Expenses

27.9 M 22.4 M 23.3 M 14.6 M 13.5 M 21 M 12.2 M 6.56 M 2.35 M 2.22 M

General and Administrative Expenses

15 M 9.43 M 7.03 M - 4.14 M - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Heat Biologics, Inc. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.88 -2.05 % $ 6.47 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.46 0.72 % $ 3.72 B usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Galectin Therapeutics Galectin Therapeutics
GALT
$ 2.32 -2.32 % $ 148 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Genmab A/S Genmab A/S
GMAB
$ 26.78 0.53 % $ 16.8 B danmarkDanmark
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 100.91 -1.13 % $ 27.2 B germanyGermany
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.08 -0.61 % $ 436 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.06 -1.54 % $ 2.93 B usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
$ 1.22 2.1 % $ 203 M usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 8.34 1.07 % $ 75.3 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.49 4.58 % $ 397 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 1.41 0.71 % $ 235 M franceFrance
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.92 -0.14 % $ 4.81 M israelIsrael
Inventiva S.A. Inventiva S.A.
IVA
$ 5.04 -1.75 % $ 138 M franceFrance
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA